[Value of the spectral analysis of radiofrequency intravascular ultrasound data in the evaluation of nonsignificant coronary lesions in chronic CHD patients].

Plaque complication depends on its composition and phenotype rather than on the degree of stenosis. Plaque rupture predominantly occurs in areas with large lipid core rich in cholesterol and thin fibrous cap. Features of unstable atheromas are mostly described in patients with acute coronary syndromes (ACS). The aim of our study was to assess the plaque characterization and arterial remodeling process in non-significant stenoses of patients with chronic coronary heart disease (CHD) using intravascular ultrasound (IVUS) radiofrequency (RF) data. Methods. The study included 22 stable patients (68% men, mean age 54+/-6 years) with CHD and clinical indications for coronary angiography (CAG). Diameter stenosis of the target coronary artery for IVUS procedure had to be less than 60%. Thin-cap fibroatheroma (TCFA) was defined as plaque burden >40% and amount of NC >10% without detectable overlying fibrous cap segment. Results. Sample size calculations based on the IVUS evaluation showed 54 atheromas in 29 target arteries. Features of vulnerability determined as TCFA were detected in 14 (26%) lesions. Compared with stable lesions VPs were associated with a greater plaque burden (48.5+/-8.0 mm2 vs 55.8+/-9.3 mm2, p=0.03), larger quantity of necrotic core (37.1+/-9.1% vs 24.0+/-12.6%, p=0.0045) and calcium content (22.7+/-8.5% vs 5.6+/-5.2%, p<0.000l), and less fibrous component (34.8+/-7.0% vs 60.4+/-12.4%, p<0.0001), respectively. Significant correlation was obtained between positive remodeling (defined as remodeling index >1.05) and NC percent area (r=0.389. p=0.005). Conclusion. In chronic CHD patients about 25% of atherosclerotic lesions responsible for less than 60% stenosis could be classified as vulnerable plaques. These borderline lesions contain more necrotic and calcium components compared with stable plaques, and are associated with positive arterial remodeling.

[Effect of hormone replacement therapy on blood serum lipids in postmenopausal women with type 2 diabetes]. / Dinamika pokazatelei lipidnogo obmena pod vliianiem zamestitel'noi gormonal'noi terapii u zhenshchin v postmenopauze s sakharnym diabetom 2-go tipa.

There are limited data concerning influence of hormone replacement therapy (HRT) on lipid profile in women with type 2 diabetes. Aim of the study was to compare changes of blood lipids during HRT in postmenopausal women with and without type 2 diabetes. Seventy seven women included in the study were assigned to 1 of 4 groups, basing on being diabetic or nondiabetic, and further subdivided into users of estrogen alone (ERT), and of estrogen plus progestin (EPRT). Effect of 6-month ERT (oral estradiol valerate 2 mg/day) and EPRT (oral estradiol valerate 2 mg/day sequentially combined with cyproterone acetate 1 mg/day) on total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides and lipoprotein (a) [Lp(a)] was separately assessed. EPRT and ERT caused decrease in LDL-C by 15% and 12%, and increase in HDL-C by 12% and 13%, respectively, in patients with diabetes (p<0.05 in all cases). LDL-C decreased by 11% and 15%, respectively, in women without diabetes (p<0.05 in all cases). Lp(a) was also reduced 25% with EPRT (p<0.01) and ERT (p<0.05). HDL-C increased 10% (p<0.05) with ERT but remained unchanged with EPRT. In conclusion, changes in all lipid parameters except Lp(a) caused by ERT and EPRT were comparable in postmenopausal women with and without type 2 diabetes.

[Six-month xenical (orlistat) therapy of patients with stable angina pectoris concomitant with obesity and hyperlipidemia]. / Opyt 6-mesiachnogo primeneniia ksenikala (orlistata) u bol'nykh stabil'noi stenokardiei s ozhireniem i giperlipidemiei.

AIM: To evaluate the efficiency of 6-month therapy with xenical (gastrointestinal lipase inhibitor) in combination with diet in patients with stable angina pectoris associated with obesity and hyperlipemia. MATERIAL AND METHODS: An open comparative randomized study of the efficiency of xenical in combination with diet was carried out in patients with stable angina pectoris concomitant with obesity and hyperlipemia. Thirty coronary patients aged 45-65 years with stable angina of effort (functional class I-II) with body weight index 28.1-45.6 kg/m2 (mean 33.5 kg/m2) were examined. All patients presented with dyslipemia (low density lipoprotein (LDL) cholesterol more than 4.14 mmol/liter, triglycerides (TG) more than 2.2 mmol/liter). Controls (n = 15) were treated with diets alone for 6 months. In the main group diets were supplemented by xenical in a dose of 360 mg/day. RESULTS: Body weight index decreased in both groups (by 9.9% in the main group and by 4.2% in the control). Body weight stabilization during 6 months of treatment and the fact that it was slow and gradual were essential. In patients treated with xenical total cholesterol level decreased by 10.9% and of LDL cholesterol by 12.2% after 6 months (p < 0.05). Changes in the levels of high density lipoprotein cholesterol and TG were insignificant. The drug did not affect the incidence of angina attacks and improved exercise tolerance after 6-month therapy. Blood biochemistry (transaminases, alkaline phosphatase, glucose, and creatinine) changed negligibly. No side effects were observed; all patients received a complete 6-month course. CONCLUSION: The results confirm that xenical (orlistat) can be used for long therapy of patients with stable angina of effort concomitant with obesity and hyperlipemia.